Natera, Inc.

NasdaqGS:NTRA 주식 리포트

시가총액: US$28.2b

Natera 향후 성장

Future 기준 점검 4/6

Natera (는) 각각 연간 62.4% 및 14.8% 수익과 수익이 증가할 것으로 예상됩니다. EPS는 연간 62.8% 만큼 성장할 것으로 예상됩니다. 자기자본이익률은 3년 후 1.6% 로 예상됩니다.

핵심 정보

62.4%

이익 성장률

62.75%

EPS 성장률

Biotechs 이익 성장25.2%
매출 성장률14.8%
향후 자기자본이익률1.59%
애널리스트 커버리지

Good

마지막 업데이트15 May 2026

최근 향후 성장 업데이트

분석 기사 • May 13

Analysts Have Made A Financial Statement On Natera, Inc.'s (NASDAQ:NTRA) First-Quarter Report

As you might know, Natera, Inc. ( NASDAQ:NTRA ) recently reported its quarterly numbers. Results overall were mixed...

Recent updates

분석 기사 • May 13

Analysts Have Made A Financial Statement On Natera, Inc.'s (NASDAQ:NTRA) First-Quarter Report

As you might know, Natera, Inc. ( NASDAQ:NTRA ) recently reported its quarterly numbers. Results overall were mixed...
내러티브 업데이트 • May 05

NTRA: MRD Leadership And New Genomic Offering Will Support Long-Term Trajectory

Analysts have kept their $300 price target on Natera unchanged, while slightly adjusting assumptions for discount rate, revenue growth, profit margins and future P/E after a mix of recent research that includes both modest target cuts and higher targets tied to updated models, guidance and a generally constructive view on the stock. Analyst Commentary Recent research paints a generally constructive picture of how Wall Street views Natera, with multiple bullish analysts fine tuning their models around updated guidance, P/E assumptions and profitability paths.
내러티브 업데이트 • Apr 20

NTRA: Oncology Execution And 2026 Catalysts Will Shape Fairly Valued Outlook

Analysts have trimmed the blended price target for Natera by about $2 to reflect updated models that incorporate slightly higher discount rates, revised revenue growth and profit margin assumptions, and a lower future P/E multiple, while still indicating constructive views from recent research coverage. Analyst Commentary Recent research on Natera presents a mix of supportive long term views and valuation recalibrations, with several firms updating models after quarterly results and competitive developments in genetic testing.
내러티브 업데이트 • Apr 05

NTRA: Molecular Residual Disease Leadership Will Drive Bullish Long Term Outlook

Analysts made a modest trim to the blended price target on Natera to about $259, reflecting slightly lower modeled revenue growth and profit margins. This adjustment comes even as several firms recently raised individual targets into the $215 to $300 range after updating their views on the company following Q4 results and new coverage initiations.
내러티브 업데이트 • Mar 22

NTRA: Molecular Residual Disease Leadership And Genomics Launch Will Shape Future Outlook

The analyst fair value estimate for Natera has been adjusted modestly higher from $257.20 to $260.65, reflecting updated models that incorporate recent Street price target revisions and assumptions for revenue growth, profit margins, and future P/E multiples. Analyst Commentary Street research around Natera has centered on how the company executes on its current guidance, maintains its position in key testing markets, and justifies premium valuation multiples through future growth and margin delivery.
Seeking Alpha • Mar 17

Natera Looks Compelling As Oncology Testing Momentum Keeps Building

Summary NTRA’s oncology franchise, led by Signatera MRD testing, is the main bull case at this point. As long as they keep building on their testing volumes, I believe this should support a long runway in cancer monitoring and recurrence detection. NTRA’s 2025 also included new product launches and added Medicare coverage, advanced early cancer detection, and broadened its molecular diagnostics portfolio. Their Foresight acquisition also strengthens NTRA’s MRD moat through PhasED-Seq technology, better testing sensitivity, and taps into lymphoma screening. I reckon NTRA’s valuation multiples are expensive. However, I think their current growth rate with Signatera justifies its price tag, which is why I lean bullish. Read the full article on Seeking Alpha
내러티브 업데이트 • Mar 07

NTRA: Elevated Oncology And 2026 Catalyst Hopes Will Likely Cap Future Upside

The updated analyst price target for Natera edges higher to a fair value estimate of $208.44 from $194.59, reflecting recent Street research where several firms lifted their targets following Q4 results, improved gross margin commentary, and expectations for a catalyst rich 2026. Analyst Commentary Recent Street research on Natera points to a mixed backdrop, with a cluster of higher price targets sitting well above the updated fair value estimate of $208.44, but also some signs of restraint as models are refreshed after Q4 results and initial 2026 guidance.
내러티브 업데이트 • Feb 21

NTRA: MRD Leadership And Broad Test Portfolio Will Support Long-Term Trajectory

Narrative Update on Natera Analysts have refreshed their views on Natera with price targets now reaching up to $300. This is supported by expectations for solid sector results, confidence in the company’s position across women's and organ health, and its growing role in the molecular residual disease market.
내러티브 업데이트 • Feb 07

NTRA: Molecular Residual Disease Leadership And FDA Progress Will Shape Future Outlook

Analysts have raised their fair value estimate for Natera to about $257 from roughly $235, citing higher assumed revenue growth, improved profit margins, and Street research that highlights the company as an established diagnostics player with a strong position in molecular residual disease, along with multiple recent price target increases up to $300. Analyst Commentary Recent Street research has been broadly constructive on Natera, with several bullish analysts lifting their price targets and emphasizing the company’s role in diagnostics and molecular residual disease.
내러티브 업데이트 • Jan 24

NTRA: Expanding MRD Adoption And New Data Will Support Long-Term Trajectory

Analysts have lifted their Natera price targets into a US$220 to US$300 range, citing recent earnings beats, raised estimates, and what they describe as strong fundamentals and a long growth runway across diagnostics and molecular residual disease testing. Analyst Commentary Recent Street research points to a cluster of higher Natera price targets, with several bullish analysts citing what they view as strong execution in diagnostics and molecular residual disease testing.
내러티브 업데이트 • Jan 09

NTRA: Expanding MRD Adoption And Trials Will Support Long-Term Revenue Trajectory

Analysts have raised their fair value estimate for Natera to $300 from $285, citing a series of higher Street price targets and ongoing enthusiasm around the company's position in women's and organ health and the molecular residual disease market. Analyst Commentary Bullish analysts have been resetting their expectations higher, with a series of price target revisions in recent months that cluster in the US$210 to US$300 range.
내러티브 업데이트 • Dec 26

NTRA: Expanding Oncology Diagnostics Will Drive Stronger Long-Term Revenue Trajectory

The analyst fair value estimate for Natera has been raised to $285 from $268, as analysts factor in stronger anticipated revenue growth and sustained momentum in key diagnostics franchises, reflected in a series of higher Street price targets. Analyst Commentary Bullish analysts have recently raised their price targets on Natera across the board, citing stronger than expected execution and a robust outlook for revenue growth.
내러티브 업데이트 • Dec 12

NTRA: Elevated Expectations Around Oncology Expansion Will Likely Constrain Future Share Returns

Natera's analyst fair value estimate has been raised sharply from approximately $115 to about $195 per share, reflecting analysts' higher long term revenue growth assumptions and confidence following a series of recent price target increases across the Street. Analyst Commentary Recent Street research has been predominantly constructive on Natera, with multiple firms lifting price targets into the $200 to $280 range and reiterating positive ratings.
내러티브 업데이트 • Nov 27

NTRA: Recent Clinical Results And Competitive Position Will Influence Future Outlook

Natera's analyst price target has been raised to $234.68 from $222.58. Analysts cite ongoing strong revenue performance, increased growth expectations, and recent research milestones as the primary drivers for the upward revision.
내러티브 업데이트 • Nov 11

NTRA: Recent Clinical Results And Cash Flow Risks Will Shape Future Performance

Natera's analyst price target has increased significantly from $202.50 to $222.58. This reflects analysts' optimism following raised estimates and expectations for continued growth, in light of recent positive clinical trial updates and industry leadership.
내러티브 업데이트 • Oct 27

Clinical Advances and AI Will Drive Expansion Into New Diagnostic Markets

Analysts raised their fair value estimate for Natera to $202.50 from $193.80. They cited momentum from recent clinical developments, positive trial updates, and ongoing strength in the company’s diagnostic and oncology business lines.
내러티브 업데이트 • Sep 28

Molecular Diagnostics And AI Integration Will Unlock New Market Opportunities

Analysts lowered Natera’s price target modestly to $193.80 as continued optimism around its liquid biopsy leadership and growth opportunities was tempered by renewed concerns about elevated valuation and margin outlook. Analyst Commentary Bullish analysts note Natera's leadership in liquid biopsy testing and large addressable markets in prenatal, minimal residual disease, and potential cancer screening, supporting long-term double-digit revenue growth.
내러티브 업데이트 • Sep 04

Molecular Diagnostics And AI Integration Will Unlock New Market Opportunities

Analysts raised Natera’s price target slightly to $198.45, citing strong Q2 results, continued leadership in liquid biopsy, robust pipeline momentum, and increasing market opportunities in cancer screening and prenatal testing. Analyst Commentary Bullish analysts cited Natera's solid Q2 beat, with significant revenue upside and sustained business momentum, leading to raised outlooks for 2025.
분석 기사 • Aug 31

Optimistic Investors Push Natera, Inc. (NASDAQ:NTRA) Shares Up 25% But Growth Is Lacking

Natera, Inc. ( NASDAQ:NTRA ) shares have had a really impressive month, gaining 25% after a shaky period beforehand...
분석 기사 • May 18

There's Reason For Concern Over Natera, Inc.'s (NASDAQ:NTRA) Price

Natera, Inc.'s ( NASDAQ:NTRA ) price-to-sales (or "P/S") ratio of 11.4x might make it look like a sell right now...
User avatar
새로운 내러티브 • May 11

Signatera, Prospera And Renasight Will Transform Diagnostics

Strong revenue growth driven by increased diagnostic volumes and strategic partnerships positively impacts Natera's earnings and future revenue potential.

이익 및 매출 성장 예측

NasdaqGS:NTRA - 애널리스트 향후 추정치 및 과거 재무 데이터 (USD Millions)
날짜매출이익자유현금흐름영업현금흐름평균 애널리스트 수
12/31/20283,95520325573913
12/31/20273,296-4416646918
12/31/20262,791-21911526218
3/31/20262,501-22672211N/A
12/31/20252,306-20876215N/A
9/30/20252,117-30994194N/A
6/30/20251,964-253105187N/A
3/31/20251,831-19085153N/A
12/31/20241,697-19059136N/A
9/30/20241,532-215-4425N/A
6/30/20241,361-292-118-56N/A
3/31/20241,209-365-197-139N/A
12/31/20231,083-435-286-247N/A
9/30/2023989-499-311-270N/A
6/30/2023931-512-387-343N/A
3/31/2023868-546-419-375N/A
12/31/2022820-548-479-432N/A
9/30/2022776-546-498-449N/A
6/30/2022723-576-492-438N/A
3/31/2022667-546-453-398N/A
12/31/2021625-472-385-335N/A
9/30/2021565-408-354-310N/A
6/30/2021505-315-280-252N/A
3/31/2021449-258-244-222N/A
12/31/2020391-230-202-183N/A
9/30/2020362-189-139-124N/A
6/30/2020342-153-117-104N/A
3/31/2020330-126-79-67N/A
12/31/2019302-125N/A-63N/A
9/30/2019286-121N/A-61N/A
6/30/2019273-128N/A-72N/A
3/31/2019262-129N/A-103N/A
12/31/2018258-128N/A-71N/A
9/30/2018243-144N/A-86N/A
6/30/2018233-142N/A-94N/A
3/31/2018223-137N/A-72N/A
12/31/2017210-138N/A-98N/A
9/30/2017207-128N/A-99N/A
6/30/2017205-126N/A-92N/A
3/31/2017205-121N/A-99N/A
12/31/2016213-100N/A-74N/A
9/30/2016221-81N/A-49N/A
6/30/2016212-72N/A-42N/A
3/31/2016205-69N/A-35N/A
12/31/2015190-70N/A-38N/A
9/30/2015187-46N/A-23N/A
6/30/2015189-28N/A0N/A

애널리스트 향후 성장 전망

수입 대 저축률: NTRA 은 향후 3년 동안 수익을 낼 것으로 예상되며, 이는 절약률(3.5%)보다 빠른 성장으로 간주됩니다.

수익 vs 시장: NTRA (는) 향후 3년 동안 평균 시장 성장보다 높은 수익을 올릴 것으로 예상됩니다.

고성장 수익: NTRA 향후 3년 내에 수익을 낼 것으로 예상됩니다.

수익 대 시장: NTRA 의 수익(연간 14.8%)이 US 시장(연간 11.7%)보다 빠르게 성장할 것으로 예상됩니다.

고성장 매출: NTRA 의 수익(연간 14.8%)은 연간 20%보다 느리게 증가할 것으로 예상됩니다.

주당순이익 성장 예측

향후 자기자본이익률

미래 ROE: NTRA의 자본 수익률은 3년 후 1.6%로 낮을 것으로 예상됩니다.

성장 기업 찾아보기

7D

1Y

7D

1Y

7D

1Y

기업 분석 및 재무 데이터 상태

데이터최종 업데이트 (UTC 시간)
기업 분석2026/05/15 13:03
종가2026/05/15 00:00
수익2026/03/31
연간 수익2025/12/31

데이터 소스

당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.

패키지데이터기간미국 소스 예시 *
기업 재무제표10년
  • 손익계산서
  • 현금흐름표
  • 대차대조표
분석가 컨센서스 추정치+3년
  • 재무 예측
  • 분석가 목표주가
시장 가격30년
  • 주가
  • 배당, 분할 및 기타 조치
지분 구조10년
  • 주요 주주
  • 내부자 거래
경영진10년
  • 리더십 팀
  • 이사회
주요 개발10년
  • 회사 공시

* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.

별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.

분석 모델 및 스노우플레이크

이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.

Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.

산업 및 섹터 지표

산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.

분석가 소스

Natera, Inc.는 30명의 분석가가 다루고 있습니다. 이 중 18명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.

분석가기관
Catherine Ramsey SchulteBaird
Luke SergottBarclays
Raymond MyersBenchmark Company